Read more

29th International Carbohydrate Symposium:
GlycoMimetics CSO Dr. John Magnani Delivers Opening Plenary Lecture

 

On July 16, 2018, GlycoMimetics CSO Dr. John Magnani delivered the opening plenary lecture at the 29th International Carbohydrate Symposium in Lisbon, Portugal. His talk entitled “Three Different Glycomimetic Drugs in Clinical Trials for Inflammatory Disease and Cancer,” described the company’s unique platform of designing innovative small molecule drugs based on the bioactive conformation of functional carbohydrates. Dr. Magnani reviewed the pre-clinical data supporting the mechanism of action of these drug candidates and how these activities translate into clinical benefit for patients under treatment. Drug candidates presented include rivipansel, a pan selectin antagonist licensed to Pfizer and currently in Phase 3 clinical trials for treatment of vaso-occlusive crisis in sickle cell disease;GMI-1271 (uproleselan), an E-selectin specific antagonist entering Phase 3 clinical studies for the treatment of acute myeloid leukemia;and GMI-1359, an antagonist of both E-selectin and CXCR4 in Phase 1 safety studies. The ability to translate the activity of these innovative compounds into clinical studies highlights our glycomimetic technology as a relatively untapped source of novel therapeutics for unmet medical needs.